下腔静脉支架置入安全性与有效性的系统评价
该系统评价检索Medline和Embase数据库,纳入33项研究共1575例患者,评估下腔静脉支架置入的安全性与有效性。中位技术成功率为100%(范围78-100%),一期通畅率75%(范围38-98%),二期通畅率91.5%(范围77-100%)。主要并发症包括肺栓塞3例、支架移位12例、大出血15例,术后即刻死亡3例。
要点
- 中位技术成功率100%(范围78-100%),一期通畅率75%(范围38-98%),二期通畅率91.5%(范围77-100%)。
- 主要并发症为肺栓塞3例、支架移位12例、大出血15例,术后即刻死亡3例。
- 多数研究报告临床症状改善,但未统一使用正式报告工具。
核心结论
- 下腔静脉支架置入的证据基础主要由单中心、回顾性、观察性研究构成,偏倚风险高。
- 尽管如此,该操作似乎安全,主要不良事件少,报告临床结局的研究显示症状和生活质量改善。
- 需要随机对照试验和前瞻性注册研究,以更大患者数量和标准化结局来改善该操作的证据基础。
研究设计与样本
- 系统评价与Meta分析,按照PRISMA指南进行,检索Medline和Embase数据库,纳入报告10例及以上患者系列中任何适应症下腔静脉支架置入安全性和有效性结局的研究。
- 共纳入33项研究,描述1575例患者。
- 适应症为恶性下腔静脉综合征229例、血栓性疾病807例、Budd-Chiari综合征501例、肝移植后下腔静脉狭窄47例。
- 男女比例为2:1,中位年龄范围为30至61岁。
主要发现
- 纳入的研究不适合进行正式Meta分析,因为30/33为无对照组的单中心回顾性研究,且结局报告存在相当大的不一致性。
- 94%的研究存在显著偏倚风险。
- 中位报告技术成功率为100%(范围78-100%),一期通畅率为75%(范围38-98%),二期通畅率为91.5%(范围77-100%)。
- 主要并发症为肺栓塞3例、支架移位12例、大出血15例,术后即刻死亡3例。
- 多数研究报告临床症状改善,但未一致使用正式报告工具。
关键数值与推荐
- 中位技术成功率100%(范围78-100%)。
- 中位一期通畅率75%(范围38-98%)。
- 中位二期通畅率91.5%(范围77-100%)。
- 主要并发症:肺栓塞3例、支架移位12例、大出血15例;术后即刻死亡3例。
临床怎么用
- 原文未据此给出推荐。
局限性
- 30/33为无对照组的单中心回顾性研究,结局报告存在相当大的不一致性,研究不适合进行正式Meta分析。
- 94%的研究存在显著偏倚风险。
- 需要随机对照试验和前瞻性注册研究,以更大患者数量和标准化结局来改善该操作的证据基础。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Inferior vena cava (IVC) stenting may provide benefit to patients with symptomatic obstruction; however, there are no devices currently licensed for use in the IVC and systematic reviews on the topic are lacking. The aim of this study was to carry out a systematic review of the literature and meta-analysis to investigate the safety and efficacy of IVC stenting in all adult patient groups. DATA SOURCES: The Medline and Embase databases were searched for studies reporting outcomes for safety and effectiveness of IVC stenting for any indication in series of 10 or more patients. REVIEW METHODS: A systematic review of the literature was carried out according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. RESULTS: Thirty-three studies were included describing 1 575 patients. Indications for stenting were malignant IVC syndrome (229 patients), thrombotic disease (807 patients), Budd-Chiari syndrome (501 patients), and IVC stenosis post liver transplantation (47 patients). The male:female ratio was 2:1 and the median age ranged from 30 to 61 years. The studies included were not suitable for formal meta-analysis as 30/33 were single centre retrospective studies with no control groups and there was considerable inconsistency in outcome reporting. There was significant risk of bias in 94% of studies. Median reported technical success was 100% (range 78 - 100%), primary patency was 75% (38 - 98%), and secondary patency was 91.5% (77 - 100%). Major complications were pulmonary embolism (three cases), stent migration (12 cases), and major bleeding (15 cases), and there were three deaths in the immediate post-operative period. Most studies reported improvement in clinical symptoms but formal reporting tools were not used consistently. CONCLUSION: The evidence base for IVC stenting consists of predominantly single centre, retrospective, observational studies that have a high risk of bias. Nonetheless the procedure appears safe with few major adverse events, and studies that reported clinical outcomes demonstrate improvement in symptoms and quality of life. Randomised controlled trials and prospective registry based studies with larger patient numbers and standardised outcome are required to improve the evidence base for this procedure.
引用
- Morris RI, Jackson N, Smith A, et al. A Systematic Review of the Safety and Efficacy of Inferior Vena Cava Stenting. Eur J Vasc Endovasc Surg. 2022. PMID: 36334902. doi:10.1016/j.ejvs.2022.11.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。